Knowledge HQ

Provides guidance on the Pharmaceutical Development section for regulatory submissions [1]. Outlines Quality by Design (QbD) principles, design space, and control strategies to ensure product quality [2, 3]. G-Rex is not referenced in this document.

Develops a non-viral TcBuster engineering method for CD70 CAR NK cells. Armored cells secrete IL-15 and resist TGF-β suppression, enhancing cytotoxicity against osteosarcoma. G-Rex is referenced in the expansion workflow schematic on day 14 as the platform for CAR NK cell expansion.

Reviews genetic engineering strategies for Vδ1 γδ T cells, specifically ADI-270. Focuses on coexpressing a CD70 CAR and dnTGFβRII to target malignancies and resist the tumor microenvironment. G-Rex is not explicitly referenced.

Explores genetic engineering of Vδ1 γδ T cells (ADI-270) with a CD70-targeted CAR and dnTGFβRII. Aims to overcome immunosuppression and host-versus-graft rejection in cancer immunotherapy. G-Rex is not referenced in this document.

This poster outlines a semi-automated GMP platform using artificial antigen presenting cells (aAPCs) to generate AML-specific CD8+ T cells. Following magnetic enrichment, the antigen-specific T cells were successfully expanded to clinically relevant numbers using G-REX expansion over a 14-day period.

The Cell Trajectory Modulation (CTM) assay provides rapid, label-free profiling of CAR T cell biophysical features like size and deformability. The study compares CAR T cells manufactured in G-Rex gas-permeable plates versus perfusion bioreactors, showing that biophysical signatures correlate with potency and phenotype.

This study demonstrates that NK cells engineered with mRNA to express an EphA2-targeted CAR exhibit enhanced cytotoxicity against pediatric sarcomas. The protocol involved expanding human primary NK cells in G-Rex 24 multi-well cell culture plates using supplemented NK MACS media and activation beads or feeder cells.

This study investigates the efficacy of Delta One T (DOT) cells against colorectal cancer. It identifies NKG2D ligand upregulation and simultaneous TIGIT/PD1 blockade as strategies to enhance cytotoxicity. The expansion protocol for producing clinical-grade DOT cells utilized the G-REX platform with OpTmizer-CTS medium.

This study develops affinity-tuned mesothelin (MSLN) CAR T cells to improve specificity and safety. Low-affinity variants showed effective tumor control with reduced off-tumor toxicity in mice. CAR T cells were expanded in G-Rex 6M well plates during the manufacturing process.

This study identifies an HLA-A*11:01-restricted TCR targeting KRAS G12V from a pancreatic cancer patient. T cells engineered with this TCR were expanded in G-Rex 24-well plates and showed specific recognition of tumor organoids, enhanced by IFN-gamma priming.

This study compares conventional and G-Rex systems for expanding BKPyV-specific T cells. G-Rex cultures resulted in higher total cell counts but increased PD-1 expression. The study highlights the need for optimization in adoptive T-cell therapy protocols for BKPyV.

This paper reports on BMS-986408, a dual DGK inhibitor that enhances PD-1 and CAR-T therapies. It improves T-cell signaling and effector function. CAR T cells were expanded in G-Rex 6M well plates during the manufacturing process for experimental assays.